The revenue of the anti-VEGF therapeutics market will increase from $12,178.0 million in 2021 at a compound annual growth rate of 1.4% from 2021 to 2030, to touch $13,812.6 million by 2030. The development of the industry is mainly driven by the approvals of the FDA to a number of drug candidates, accompanied by R&D activities.
Eylea held the largest share in the anti-VEGF therapeutics market, in excess of 60%, in the year 2021, a satiation that is not predicted to alter in the years to come. This is mainly because of the continuous R&D on this drug. For example, Regeneron is undertaking a study to find out if an 8mg dosage can be more helpful for wet AMD patients than the presently approved 2mg dose.